HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.

Abstract
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis.
AuthorsCarlos Hernandez, Hugo Arasanz, Luisa Chocarro, Ana Bocanegra, Miren Zuazo, Gonzalo Fernandez-Hinojal, Ester Blanco, Ruth Vera, David Escors, Grazyna Kochan
JournalInternational journal of molecular sciences (Int J Mol Sci) Vol. 21 Issue 7 (Mar 31 2020) ISSN: 1422-0067 [Electronic] Switzerland
PMID32244396 (Publication Type: Journal Article, Review)
Chemical References
  • Biomarkers
  • CTLA-4 Antigen
  • CTLA4 protein, human
  • Immune Checkpoint Inhibitors
Topics
  • Biomarkers
  • Blood Cells
  • CD4-Positive T-Lymphocytes
  • CD8-Positive T-Lymphocytes
  • CTLA-4 Antigen
  • Humans
  • Immune Checkpoint Inhibitors (therapeutic use)
  • Immunotherapy
  • Killer Cells, Natural
  • Macrophages
  • Monocytes
  • Myeloid-Derived Suppressor Cells (metabolism)
  • Neoplasms (drug therapy)
  • Tumor Microenvironment (immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: